3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, Follicular
5
Sarcoma, Synovial
4
Sarcoma
4
Rhabdoid Tumor
3
Mesothelioma
3
Lymphoma, Non-Hodgkin
3
Lymphoma, B-Cell
3
Recurrence
2
Lymphoma, Mantle-Cell
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma
2
Wilms Tumor
1
Tertiary Lymphoid Structures
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Medulloblastoma
1
Hodgkin Disease
1
Histiocytosis, Langerhans-Cell
1
Hepatoblastoma
1
Hematologic Neoplasms
1
Glioma
1
Ependymoma
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Interventions
tazemetostat
1
relatlimab
1
durvalumab
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Tertiary Lymphoid Structures
×
tazemetostat
×
Clear all
NCT04705818
2026-03-06
CAIRE
Institut Bergonié
Phase 2
Completed
164 enrolled